Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The acquisition of SPR Therapeutics will allow Medtronic to expand its portfolio of neuromodulator medical devices. The deal is expected to close in 2027.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.
An imaging industry supplier best known for a widely adopted radiology reporting platform is partnering on radiological artificial intelligence with a company that pioneered GPUs and accelerated computing.
An established radiopharmaceutical can now be applied with the FDA’s blessing when symptoms of cognitive decline point to the second most common form of degenerative dementia (after only Alzheimer’s disease).
With its 108th scientific assembly and annual meeting a little more than two weeks away, the Radiological Society of North America is encouraging attendees to experience 2022’s big show virtually—even if they’ll be there in person.
RapidAI has been cleared for U.S. marketing of updated AI-outfitted software that quickly detects or rules out acute brain hemorrhage on unenhanced CT.
More than 30% of surveyed PACS users are looking around for a potential replacement, according to an 82-page report from KLAS. “The U.S. PACS market is poised for change," the report's authors wrote.
Contrary to older research that showed neuroimaging emerging as the single most dominating cost contributor in ischemic stroke care for older Americans, a new study shows treatment and other line items account for bigger slices of the bill.
A three-site imaging operation in Hawaii has been turning away patients since Oct. 20 due to what its management initially described as unspecified “technical difficulties.”